THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.27] ID: TIP-MED-000231

Levodopa + Carbidopa (Co-Careldopa) & Pramipexole

Active Ingredient / Scientific Identity: Levodopa + Carbidopa • Class: Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & Non-Ergot D2/D3 Dopamine Agonist

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Levodopa + Carbidopa (Co-Careldopa) & Pramipexole ([11.27] | ID: TIP-MED-000231) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-27-levodopa-carbidopa-co-careldopa-pramipexole/
Generic / Entity NameLevodopa + Carbidopa (Co-Careldopa) & Pramipexole ([11.27])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassDopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & Non-Ergot D2/D3 Dopamine Ag
Available Dosage FormsLevodopa + Carbidopa IR Scored Tablets: 100/10 mg (Syndopa-110), 100/25 mg (Syndopa-Plus), 250/25 mg; CR Table
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepa
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Levodopa + Carbidopa (Co-Careldopa) & Pramipexole (TIP-MED-000231, Reference Code [11.27]) is classified under Neurology & Antiepileptic Medicines (Ch 11) as a Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & Non-Ergot D2/D3 Dopamine Agonist. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.27], p. 153): Syndopa-110 / Syndopa-Plus / Syndopa-275 / Syndopa-CR (Sun Pharma), Tidomet-LS / Plus / CR (Torrent); Pramipexole: Pramipex (Sun), Pexep (Intas), Remipex — Strengths & Dosage Forms: Levodopa + Carbidopa IR Scored Tablets: 100/10 mg (Syndopa-110), 100/25 mg (Syndopa-Plus), 250/25 mg; CR Tablets: 100/25 mg, 200/50 mg. Pramipexole IR: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg; ER: 0.375 mg, 0.75 mg, 1.5 mg.
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.27], p. 153): Syndopa-110 / Syndopa-Plus / Syndopa-275 / Syndopa-CR (Sun Pharma), Tidomet-LS / Plus / CR (Torrent); Pramipexole: Pramipex (Sun), Pexep (Intas), Remipex — Strengths & Dosage Forms: Levodopa + Carbidopa IR Scored Tablets: 100/10 mg (Syndopa-110), 100/25 mg (Syndopa-Plus), 250/25 mg; CR Tablets: 100/25 mg, 200/50 mg. Pramipexole IR: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg; ER: 0.375 mg, 0.75 mg, 1.5 mg.
Dosage Forms & Available Strengths:
Levodopa + Carbidopa IR Scored Tablets: 100/10 mg (Syndopa-110), 100/25 mg (Syndopa-Plus), 250/25 mg; CR Tablets: 100/25 mg, 200/50 mg. Pramipexole IR: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg; ER: 0.375 mg, 0.75 mg, 1.5 mg.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Carbidopa blocks peripheral conversion of Levodopa so central striatal dopamine is restored; Pramipexole directly stimulates postsynaptic D2/D3 receptors.

4. Therapeutic Indications & Evidence-Supported Uses

  • Idiopathic Parkinson's disease (bradykinesia, rigidity, resting tremor) and primary Restless Legs Syndrome (Pramipexole 0
  • 125–0
  • 5 mg 2h before bedtime)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Levodopa + Carbidopa: Start 100/25 mg PO TDS (delivering >=75 mg/day Carbidopa to block peripheral nausea); titrate every 3–7 days. Pramipexole: Start 0.125 mg TDS (or 0.375 mg ER OD); titrate every 5–7 days to 1.5–4.5 mg/day.

Administration & Meal Timing: Take Immediate-Release Levodopa+Carbidopa 30–45 min BEFORE meals (high-protein meals compete via large neutral amino acid transporters!). | Strict clock-timed dosing (e.g., 08:00, 12:00, 16:00, 20:00) to prevent 'wearing-off' motor freezing.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.
Elimination & Renal Adjustment:
Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.
Hepatic Impairment Considerations:
Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • HYPERPYREXIA-PARKISONISM SYNDROME ON ABRUPT WITHDRAWAL & SUDDEN SLEEP ATTACKS: Abrupt cessation precipitates fatal Neuroleptic Malignant-like Syndrome (rigid hyperthermia, rhabdomyolysis). Pramipexole causes sudden daytime sleep attacks and impulse-control disorders (pathological gambling/bingeing).

Key Clinical Precautions: Renal: Reduce Pramipexole frequency if CrCl <50 mL/min (start 0.125 mg BD if CrCl 20–50; 0.125 mg OD if CrCl <20). Hepatic: Caution in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, orthostatic hypotension, peak-dose choreiform dyskinesias, 'wearing-off' motor fluctuations, vivid dreams/hallucinations, reddish-brown discolouration of urine/sweat/saliva (harmless).
  • Parkinsonism-hyperpyrexia crisis (abrupt withdrawal), sudden onset of sleep while driving, impulse-control disorder, visual hallucinations, melanoma risk.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • STRICTLY AVOID Typical/Atypical D2 Antipsychotics (Haloperidol, Risperidone, Olanzapine) and Metoclopramide/Prochlorperazine (block striatal D2 receptors & worsen Parkinsonism! Use Domperidone for nausea or Quetiapine/Clozapine for psychosis)
  • Separate oral Iron by >=2 hours (chelates Levodopa!)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Take doses at the exact prescribed minute every day; separate Iron tablets by 2 hours; harmless dark urine/sweat may occur; never use Metoclopramide for vomiting; never stop tablets suddenly.
  • Meal & Clock Timing Instruction: Take Immediate-Release Levodopa+Carbidopa 30–45 min BEFORE meals (high-protein meals compete via large neutral amino acid transporters!). (Strict clock-timed dosing (e.g., 08:00, 12:00, 16:00, 20:00) to prevent 'wearing-off' motor freezing.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes (Levodopa + Carbidopa 100/10, 100/25, 250/25) | Compendia: NFI 7th Ed 2026 / NLEM 2022

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Levodopa + Carbidopa IR Scored Tablets: 100/10 mg (Syndopa-110), 100/25 mg (Syndopa-Plus), 250/25 mg; CR Tablets: 100/25 mg, 200/50 mg. Pramipexole IR: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg; ER: 0.375 mg, 0.75 mg, 1.5 mg.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.27] (p. 153)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-27-levodopa-carbidopa-co-careldopa-pramipexole/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.